194 related articles for article (PubMed ID: 21468264)
41. AIDS-related central nervous system lymphomas.
Chamberlain MC; Kormanik PA
J Neurooncol; 1999 Jul; 43(3):269-76. PubMed ID: 10563433
[TBL] [Abstract][Full Text] [Related]
42. Primary Oculocerebral Lymphoma: MTX Polychemotherapy Alone on Intraocular Disease Control.
Nguyen DT; Houillier C; Choquet S; Cassoux N; Soussain C; Le Cossec C; Legarf-Tavernier M; Costopoulos M; LeHoang P; Bodaghi B; Omuro A; Hoang-Xuan K; Touitou V
Ophthalmology; 2016 Sep; 123(9):2047-50. PubMed ID: 27137876
[No Abstract] [Full Text] [Related]
43. Systemic chemotherapy alone for patients with non-acquired immunodeficiency syndrome-related central nervous system lymphoma: a pilot study of the BOMES protocol.
Cheng AL; Yeh KH; Uen WC; Hung RL; Liu MY; Wang CH
Cancer; 1998 May; 82(10):1946-51. PubMed ID: 9587129
[TBL] [Abstract][Full Text] [Related]
44. A new prognostic model using absolute lymphocyte count in patients with primary central nervous system lymphoma.
Jang JE; Kim YR; Kim SJ; Cho H; Chung H; Lee JY; Park H; Kim Y; Cheong JW; Min YH; Kim JS
Eur J Cancer; 2016 Apr; 57():127-35. PubMed ID: 26918738
[TBL] [Abstract][Full Text] [Related]
45. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
Schorb E; Finke J; Ferreri AJ; Ihorst G; Mikesch K; Kasenda B; Fritsch K; Fricker H; Burger E; Grishina O; Valk E; Zucca E; Illerhaus G
BMC Cancer; 2016 Apr; 16():282. PubMed ID: 27098429
[TBL] [Abstract][Full Text] [Related]
46. Rituximab, methotrexate, procarbazine and lomustine (R-MPL) for the treatment of primary Central nervous system lymphoma.
Lebel E; Goldschmidt N; Siegal T; Lossos A; Rosenberg S; Makranz C; Linetski E; Gatt ME; Gural A; Saban R; Lavie D; Vainstein V; Zimran E; Avni B; Grisaro S; Shaulov A; Nachmias B
Leuk Lymphoma; 2022 Sep; 63(9):2102-2108. PubMed ID: 35491706
[TBL] [Abstract][Full Text] [Related]
47. Secondary analysis of Radiation Therapy Oncology Group study (RTOG) 9310: an intergroup phase II combined modality treatment of primary central nervous system lymphoma.
Fisher B; Seiferheld W; Schultz C; DeAngelis L; Nelson D; Schold SC; Curran W; Mehta M
J Neurooncol; 2005 Sep; 74(2):201-5. PubMed ID: 16193393
[TBL] [Abstract][Full Text] [Related]
48. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).
Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274
[TBL] [Abstract][Full Text] [Related]
49. Influence of methotrexate exposure on outcome in patients treated with MBVP chemotherapy for primary central nervous system lymphoma.
Blasco H; Senecal D; Le Gouge A; Pinard E; Benz-de Bretagne I; Colombat P; Hulot JS; Chatelut E; Le Guellec C
Br J Clin Pharmacol; 2010 Sep; 70(3):367-75. PubMed ID: 20716237
[TBL] [Abstract][Full Text] [Related]
50. Interim
Jo JC; Yoon DH; Kim S; Lee K; Kang EH; Park JS; Ryu JS; Huh J; Park CS; Kim JH; Lee SW; Suh C
Ann Hematol; 2017 Sep; 96(9):1509-1515. PubMed ID: 28725988
[No Abstract] [Full Text] [Related]
51. CHOD/BVAM chemotherapy and whole-brain radiotherapy for newly diagnosed primary central nervous system lymphoma.
Laack NN; O'Neill BP; Ballman KV; O'Fallon JR; Carrero XW; Kurtin PJ; Scheithauer BW; Brown PD; Habermann TM; Colgan JP; Gilbert MR; Hawkins RB; Morton RF; Windschitl HE; Fitch TR; Pajon ER;
Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):476-82. PubMed ID: 20800387
[TBL] [Abstract][Full Text] [Related]
52. Salvage therapy and late neurotoxicity in patients with recurrent primary CNS lymphoma treated with a modified ProMACE-MOPP hybrid regimen.
Yamanaka R; Shinbo Y; Sano M; Homma J; Tsuchiya N; Yajima N; Tamura T; Hondoh H; Takahashi H; Morii K; Onda K; Tanaka R
Leuk Lymphoma; 2007 Jun; 48(6):1119-26. PubMed ID: 17577775
[TBL] [Abstract][Full Text] [Related]
53. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study.
Bromberg JEC; Issa S; Bakunina K; Minnema MC; Seute T; Durian M; Cull G; Schouten HC; Stevens WBC; Zijlstra JM; Baars JW; Nijland M; Mason KD; Beeker A; van den Bent MJ; Beijert M; Gonzales M; de Jong D; Doorduijn JK
Lancet Oncol; 2019 Feb; 20(2):216-228. PubMed ID: 30630772
[TBL] [Abstract][Full Text] [Related]
54. Prognostic value of immunohistochemical profile and response to high-dose methotrexate therapy in primary CNS lymphoma.
Momota H; Narita Y; Maeshima AM; Miyakita Y; Shinomiya A; Maruyama T; Muragaki Y; Shibui S
J Neurooncol; 2010 Jul; 98(3):341-8. PubMed ID: 20012911
[TBL] [Abstract][Full Text] [Related]
55. Role of rituximab in treatment of patients with primary central nervous system lymphoma: a retrospective analysis of the Czech lymphoma study group registry.
Mocikova H; Pytlik R; Sykorova A; Janikova A; Prochazka V; Vokurka S; Berkova A; Belada D; Campr V; Buresova L; Trneny M;
Leuk Lymphoma; 2016 Dec; 57(12):2777-2783. PubMed ID: 27087066
[TBL] [Abstract][Full Text] [Related]
56. Temozolomide as a Single Agent Maintenance Therapy in Elderly Patients With Primary CNS Lymphoma.
Faivre G; Butler MJ; Le I; Brenner A
Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):665-669. PubMed ID: 31351990
[TBL] [Abstract][Full Text] [Related]
57. Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survival.
Martinez-Calle N; Poynton E; Alchawaf A; Kassam S; Horan M; Rafferty M; Kelsey P; Scott G; Culligan DJ; Buckley H; Lim YJ; Ngu L; McCulloch R; Rowntree C; Wright J; McKay P; Fourali S; Eyre TA; Smith J; Osborne W; Yallop D; Linton K; Fox CP; Cwynarski K
Br J Haematol; 2020 Aug; 190(3):394-404. PubMed ID: 32232989
[TBL] [Abstract][Full Text] [Related]
58. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma.
Abramson JS; Hellmann M; Barnes JA; Hammerman P; Toomey C; Takvorian T; Muzikansky A; Hochberg EP
Cancer; 2010 Sep; 116(18):4283-90. PubMed ID: 20564149
[TBL] [Abstract][Full Text] [Related]
59. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
[TBL] [Abstract][Full Text] [Related]
60. Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments.
Bessell EM; López-Guillermo A; Villá S; Verger E; Nomdedeu B; Petit J; Byrne P; Montserrat E; Graus F
J Clin Oncol; 2002 Jan; 20(1):231-6. PubMed ID: 11773174
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]